Close Menu

NEW YORK – In the midst of the coronavirus pandemic, diagnostics companies have been frantically developing new tests for SARS-CoV-2. This week Iceni Diagnostics threw its hat in the ring, pledging to deliver a rapid, point-of-care test that could differentiate the virus from more common strains of influenza using artificial glycan receptors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.